Related Experiment Video

Updated: May 8, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

[Relationship between cholesteryl ester transfer protein gene -629C→A mutations with HDL-C levels and coronary heart

Jing Gao1, Yong-min Mao, Hong-lia Cong

  • 1Tianjin Cardiovascular Institute, Tianjin Chest Hospital, Tianjin, China.

Zhonghua Xin Xue Guan Bing Za Zhi
|September 12, 2013
PubMed

Insights

The CETP gene -629C/A polymorphism is less frequent in Tianjin Han Chinese. Paradoxically, the variant AA genotype, linked to lower CETP and higher HDL-C, increases coronary heart disease risk.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Biochemistry

Context:

  • The cholesteryl ester transfer protein (CETP) plays a role in lipid metabolism.
  • Genetic variations in the CETP gene promoter may influence lipid levels and cardiovascular risk.
  • Understanding these relationships is crucial for developing targeted prevention strategies.

Purpose:

  • To investigate the association between the CETP gene -629C/A polymorphism, serum CETP levels, lipid profiles, and coronary heart disease (CHD) in the Tianjin Han Chinese population.
  • To compare allele and genotype frequencies with other populations.
  • To explore the paradoxical relationship between lipid profiles and CHD risk.

Summary:

  • A case-control study in Tianjin, China, analyzed 429 CHD cases and 275 controls.
  • The -629A allele frequency was lower than in other populations. The AA genotype showed reduced CETP levels and higher HDL-C.
  • Carriers of CA/AA genotypes and the A allele had significantly higher CHD risk, independent of HDL-C levels.

Impact:

  • This study reveals a significant difference in CETP gene polymorphism frequencies in the Tianjin Han Chinese population.
  • The findings suggest that CETP gene variations may contribute to coronary risk through mechanisms beyond HDL-C levels.
  • Highlights the need for further research into the complex interplay between genetics, lipid metabolism, and cardiovascular outcomes.
Abstract

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...